A Liquid Biopsy for Local Recurrences

AACR shared four cutting-edge highlights from the AACR-AHNS conference (July 7-8, 2023), including Droplet Biosciences data presented by co-founder Dr. José Zevallos that shows lymph is superior to plasma at predicting local recurrences. August 3, 2023  Read the full article in Cancer Research Catalyst: The Official Blog of the American Association for Cancer Research: 

Droplet Biosciences Releases First Research Data, Demonstrates Lymph Liquid Biopsy‘s Ability to Predict Locoregional Recurrence

Montréal, QC, Canada – July 8, 2023 – Droplet Biosciences, a pioneer in harnessing the power of lymphatic fluid to provide earlier and more sensitive cancer diagnostics, released its initial research data this morning at AACR-AHNS Head and Neck Conference: Innovating through Basic, Clinical and Translational Research. The abstract Detection of minimal residual disease in post-surgical […]

Droplet Biosciences Announces Lymph Diagnostic Platform to Help Prevent Cancer Recurrence

With an $8 million seed investment led by The Engine, Droplet will develop a novel lymph liquid biopsy for earlier, more precise care following surgery.  https://www.businesswire.com/news/home/20230316005040/en/Droplet-Biosciences-Announces-Lymph-Diagnostic-Platform-to-Help-Prevent-Cancer-Recurrence CAMBRIDGE, MA – March 16, 2023 – Droplet Biosciences today announced an $8 million seed investment to establish proof of concept for the company’s technology. While the lymphatic system’s […]

Droplet Biosciences Targets Lymph Fluid in New Residual Cancer Detection Strategy

With an $8M seed investment led by The Engine, Droplet will develop a liquid biopsy test using lymphatic fluid rather than blood plasma as a source for detecting cancer-associated DNA alterations. March 16, 2023 Read the full article on GenomeWeb: https://www.genomeweb.com/cancer/droplet-biosciences-targets-lymph-fluid-new-residual-cancer-detection-strategy#.ZBMW5-zMKrc